Obesity alters how medications work, increasing the risk of underdosing, overdosing, and unknown interactions. Are package ...

In this video at Obesity Medicine 2025, Harold E. Bays, MD, FOMA, FTOS, FACC, FASPC, FNLA, discusses highlights from his talk ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

A new expert review endorses GLP-1 RAs and other medications for sustainable weight loss in children with obesity and MASLD.

Health360 focusses on India's obesity epidemic and Prime Minister Modi's recent call to tackle it. Experts discuss the rise ...

The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...

A group of Democratic senators are calling on Health and Human Services Secretary Robert F. Kennedy Jr. to keep a proposed ...

Obesity is driving up rates of type 2 diabetes, hypertension, heart disease, fatty liver, sleep apnoea, and even cancers. A ...

8%) of GLP-1/GIP RAs. A total of 359 participants (35%) reported current use of these obesity drugs, 85% reported prior use, and 111 (11%) reported interest in use. An understanding of possible ...

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...

Adults with obesity who used medication and received guidance on resistance training and nutrition lost substantially more ...